Clidinium bromide

Not to be confused with Acridinium bromide or Aclidinium bromide.
Clidinium bromide
Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a601036
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration
Oral
ATC code A03CA02 (WHO) (combination with psycholeptics)
Legal status
Legal status
Pharmacokinetic data
Bioavailability Low
Excretion Renal and biliary
Identifiers
CAS Number 7020-55-5 YesY 3485-62-9
PubChem (CID) 2784
IUPHAR/BPS 366
DrugBank DB00771 YesY
ChemSpider 2682 YesY
UNII BO76JF850N YesY
ChEMBL CHEMBL1200950 N
Chemical and physical data
Formula C22H26NO3+
Molar mass 352.447 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Clidinium bromide (INN) is an anticholinergic (specifically a muscarinic antagonist) drug.[1] It may help symptoms of cramping and abdominal/stomach pain by decreasing stomach acid, and slowing the intestines. It is commonly prescribed in combination with chlordiazepoxide (a benzodiazepine derivative) using the brand name Librax.

Uses

Peptic ulcer disease

Used in fixed combination with chlordiazepoxide as adjunctive therapy in the treatment of peptic ulcer disease; however, no conclusive data that antimuscarinics aid in the healing, decrease the rate of recurrence, or prevent complications of peptic ulcers.[2]

With the advent of more effective therapies for the treatment of peptic ulcer disease, antimuscarinics have only limited usefulness in this condition.

GI motility disturbances

Used in fixed combination with chlordiazepoxide in the treatment of functional GI motility disturbances (e.g., irritable bowel syndrome).

Has limited efficacy in treatment of GI motility disturbance and should only be used if other measures (e.g., diet, sedation, counseling, amelioration of environmental factors) have been of little or no benefit.

Acute enterocolitis

Used in fixed combination with chlordiazepoxide in the treatment of acute enterocolitis. However, antimuscarinics should be used with extreme caution in patients with diarrhea or ulcerative colitis.

Mechanism of action

Clidinium inhibits muscarinic acetylcholine receptors on smooth muscles, secretory glands, and in the central nervous system to relax smooth muscle and decrease biliary tract secretions.[3]

References

  1. "Clidinium bromide". Drugs.com. Retrieved August 24, 2013.
  2. "Clidinium Bromide Monograph". Drugs.com. Retrieved August 24, 2013.
  3. 2014 Nurses Drug Handbook (13th ed.). Burlington, MA: Jones & Bartlett Learning. 2014. pp. 245–6. ISBN 978-1-284-03115-7.
This article is issued from Wikipedia - version of the 12/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.